Full-Time
EHR data parsing with oncology LLMs
No salary listed
New York, NY, USA
In Person
Based in New York City and able to work in the office regularly.
See people who can refer or advise you
Triomics uses generative AI to turn unstructured health-record data in oncology into actionable insights. Its OncoLLM analyzes doctor notes, PDFs, and lab results to extract relevant clinical information, with Prism automating patient-to-clinical-trial matching and Harmony curating EHR data for quality reporting and cohort analysis. By integrating with existing EHR systems, it speeds up tasks that used to require hours of manual review and can match patients to trials in minutes with high accuracy. The goal is to reduce manual data review in cancer research and care, accelerate trial enrollment, and support precision oncology for cancer centers, academic medical centers, and health systems.
Company Size
51-200
Company Stage
Series B
Total Funding
$54.2M
Headquarters
New York City, New York
Founded
2020
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Flexible Work Hours
Meal Benefits
The Series B round was led by Battery Ventures.
Triomics, a generative AI startup, has secured $15M in Series A funding to enhance cancer clinical trials matching. Founded by Sarim Khan and Hrituraj Singh, the company's OncoLLM platform uses AI to quickly match patients with trials, improving efficiency in cancer care. With this funding from Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator, Triomics plans to expand its reach and develop its platform further.
For cancer patients, medicines administered in clinical trials can help save or extend lives. But despite thousands of trials in the United States each
Triomics has filed a notice of an exempt offering of securities to raise $14,135,000.00 in New Equity Investment. Triomics has filed a notice of an exempt offering of securities to raise $14,135,000.00 in New Equity Investment.According to filings with the U.S. Securities and Exchange Commission, Triomics is raising $14,135,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Sarim Khan played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.About TriomicsTriomics combines the most advanced clinical trial tracking software with a global network of supersites and partners to deliver rapid, cost-effective, high quality clinical trials that pass even the most rigorous regulatory scrutiny. Triomics Harmony© is powering a host of next-generation applications of healthcare data and systems for advancing clinical research by harnessing the growing maturity of US healthcare on FHIR and addressing its current limitations, enabling us to empower healthcare organizations at any phase of their FHIR adoption journey.To learn more about Triomics, visit http://www.triomics.in/Contact:Sarim Khan, Chief Executive Officer707-227-9112https://www.linkedin.com/in/sarim-khan-triomics/SOURCE: http://www.intelligence360.ioCopyright (c) 2023 SI360 Inc. All rights reserved